Introduction
Much recent interest has been focused on the transfusionrequirements of intensive care unit (ICU) patients and how best to reduce patient exposure tounnecessary transfusions (and so avoid the associated risks). Previous workhas identified the ICU population as having a transfusion requirement of 2-4units/ week.ICU patients, particularly those with sepsis, appear unable to mount anerythropoietic response to compensate for their anemia. It is uncertainwhether this is as a result of inappropriately low erythropoietin productionfor the hemoglobin level or a failure to respond to endogenouserythropoietin.
Aims
This study aimed to determine whether the administration ofrecombinant human erythropoietin (rHuEPO) to critically ill patients wouldreduce the requirements for red blood cell (RBC) transfusions.
The study was a prospective, randomized, double-blind,placebo-controlled trial carried out in three tertiary care ICUs andstudied a total of 160 patients (80 in each of the placebo and rHuEPOgroups). Patients who fulfilled the study criteria were randomized andentered the trial on day 3 of their ICU admission. rHuEPO was administeredsubcutaneously at a dose of 300 units/kg for a total of 5days. Subsequently, the study drug was administered on alternate days for aminimum of 2 weeks, or until ICU discharge. The rHuEPO was temporarilywithheld when the hematocrit (Hct) reached > 38% and restarted when the Hctfell below 38%.Outcomes examined were cumulative blood transfusion requirements during the study period and transfusion independence between study days 8 and 42.
Results
Of 1778 patients admitted to the three ICUs over the studyperiod, 329 were eligible but only 160 were enrolled (most commonly due torefusal to consent). The study populations were well matched and did notdiffer from the patients who did not consent to participate in the study.Cumulative transfusion requirements for the rHuEPO group were significantlyless than the placebo group (166 total units in the rHuEPO group versus 305 totalunits for the placebo group). Each patient received a mean of 8.3 ± 4.5 dosesof rHuEPO.When transfusion independence was examined, 45% of patients in the rHuEPO groupeither received a blood transfusion between day 8 and 42 or died beforestudy day 42, compared to 55% patients in the placebo group. There was nosignificant difference in the two groups in mortality or adverse events.
Discussion
The authors conclude that administration of rHuEPO to ICUpatients resulted in a significant reduction in blood transfusion requirements. They also concluded that the ability of this ICU population torespond to rHuEPO may indicate that the anemia seen in this population isdue to a blunted erythropoietic response, as well as an impaired ability torespond to endogenous erythropoietin. They suggested that further studieswere needed to identify the potential benefits of avoiding RBCtransfusion.
